Comparison of different preparations of botulinumtoxin A in the treatment of cervical dystonia
- Author:
Kathrin Brockmann
;
Katherine Schweitzer
;
Gaby Beck
;
Tobias Wächter
- Publication Type:Journal Article
- From:Neurology Asia
2012;17(2):115-119
- CountryMalaysia
- Language:English
-
Abstract:
Background and Objectives: Botulinum neurotoxin A (BoNT-A) is the fi rst line treatment for cervical
dystonia (CD). Three different preparations are available: abobotulinumtoxinA, onabotulinumtoxinA,
and incobotulinumtoxinA. However, potencies between these preparations vary and the products
are therefore not easily interchangeable. Methods: We retrospectively compared the treatment plans
and outcome of 51 patients with CD who were treated either with abobotulinumtoxinA (n = 19),
onabotulinumtoxinA (n = 20), or incobotulinumtoxinA (n = 12). Results: There were no differences
between the three treatment groups in respect to time of fi rst improvement of symptoms (TIS), duration
of symptom relieve (DSR), or maximum benefi t (MaxB). However, the total units used for treatment
in the abobotulinumtoxineA group was signifi cantly higher than in both other groups, thus resulting
in a conversion ratio of 4:1for abobotulinumtoxinA to onabotulinumtoxinA and a conversion ratio of
4.3:1 for abobotulinumtoxinA to incobotulinumtoxinA.
Conclusion: In clinical practice, the conversion ratio between abototulinumtoxinA and
onabotulinumtoxineA might be higher than previously indicated by prospective studies or in mouse
assays. Consequently, lager studies are needed to determine the conversion ratio of the different
preparations available as well as the optimization of doses and selection of preparation, therefore
resulting in improved cost-effectiveness of different treatment options in clinical practice.
- Full text:P020150709418621626524.pdf
